MGNX Macrogenics Inc

Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

$28.94  -1.61 (-5.27%)
As of 05/12/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/10/2013
Outstanding shares:  60,036,407
Average volume:  682,632
Market cap:   $1,829,309,321
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    556099109
ISIN:        US5560991094
Sedol:      BFDV8K0
Valuation   (See tab for details)
PE ratio:   -13.46
PB ratio:   5.23
PS ratio:   16.93
Return on equity:   -38.29%
Net income %:   -124.17%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy